Life Technologies, now a brand of Thermo Fisher Scientific, traces its roots back to 1962 with the creation of Grand Island Biological Company (GIBCO) in Grand Island, New York, making serum harvested from horses raised on their land. The original Life Technologies, Inc., a subsidiary of Dexter Corp., was founded in 1983 by the merger of Bethesda Research Laboratories, Inc. and GIBCO Corporation. In 2000, Life Technologies was bought out by Invitrogen. Eight years later, following Invitrogen Corporation’s acquisition of Applied Biosystems Inc., Invitrogen renamed itself, creating the new Life Technologies Corp. In 2014, Life Technologies became the fourth premier brand within Thermo Fisher, the world leader in serving science.

Life Technologies Timeline

2014

  • Acquisition of Life Technologies by Thermo Fisher Scientific completed, creating an unrivaled leader in serving research, specialty diagnostics and applied markets. As part of the merged company, the Life Technologies brand remains an innovator in the life sciences and a supplier of products across numerous research and applied markets.

2013

  • Thermo Fisher Scientific announces its intention to acquire Life Technologies.

2012

  • Life Technologies releases GlobalFiler™ Kit, setting new standard for faster criminal DNA forensic testing.
  • Life Technologies launches Pervenio™ Lung RS, first genetic test for identifying early-stage lung cancer patients at high risk of recurrence.

2011

  • Ion Personal Genome Machine is used by Life scientists and investigators in Germany to identify source of European E. coli outbreak in three days. Within two weeks, Life begins shipping rapid detection kits to Europe.

2010

  • Life Technologies acquires Ion Torrent, developer of semi-conductor next generation sequencing technology and launches the Ion Personal Genome Machine (PGM)™, which becomes the fastest selling sequencing instrument in the history of the market.

2008

  • Life Technologies’ kits for detecting possible E. coli O157 contamination in food are utilized at the 2008 Summer Olympic Games in Beijing, China.
  • Life Technologies Corporation (NASDAQ:LIFE) forms with the merger of Invitrogen Corporation and Applied Biosystems Inc.

2002

  • Applied Biosystems reaches revenues of $1.6 billion and offers products including the SOLiD System, among the first next-generation DNA sequencing platforms.

2000

  • Applied Biosystems is released as a publicly traded company (NYSE:AB).
  • Invitrogen merges with Life Technologies/GIBCO, one of the longest standing companies in the industry and a world leader in molecular biology and cell culture supplies for the life science industry.

1999

  • Invitrogen, with sales upward of $33 million, goes public (NASDAQ: IVGN) raising $48.1 million in its initial public offering. The company also acquires Novex, a leader in cloned protein characterization.

1987

  • Lyle Turner, Joe Fernandez and William MacConnell found Invitrogen, focused on developing products for the molecular biology research market for kits, reagents and services.

1983

  • Applied Biosystems gains rights to automated DNA sequencing from the California Institute of Technology. The company is acquired by Perkin Elmer.

1981

  • Applied Biosystems is founded by Sam Eletr and Andre Marion as a biochemical and diagnostic research instrument manufacturer.

1975

  • Production of monoclonal antibodies is invented by Cesar Milstein and Georges J.F. Kohler of GIBCO, for which they shared the Nobel Prize in Physiology or Medicine in 1984 with Niels Kaj Jerne.

1964

  • GIBCO cultures the first stem cells.

1962

  • Grand Island Biological Company (Gibco) is founded in Grand Island, New York. The company supplied serum harvested from horses raised on their own land.